Multi-Omics Analysis Of Pbmcs Revealed Distinct Biological Differences Between Hemodialysis And Peritoneal Dialysis
For individuals with kidney failure, dialysis is a life-sustaining treatment, with hemodialysis and peritoneal dialysis being two common types. While doctors understand the clinical differences between these two methods, the underlying biological changes at a cellular level have been less clear.
Recent research utilized a comprehensive approach called “multi-omics” to investigate these differences. This involved looking at thousands of proteins (proteomics) and gene activities (transcriptomics) within specific immune cells from the blood, known as peripheral blood mononuclear cells (PBMCs), of patients undergoing either hemodialysis or peritoneal dialysis. PBMCs are crucial for our immune system, and understanding how dialysis affects them can provide insights into patient health.
The study found significant molecular distinctions between the two groups. Specifically, patients on hemodialysis showed a consistent increase in a particular immune-regulating factor called IRF8. Furthermore, the analysis indicated that the cells from hemodialysis patients exhibited signs associated with cellular senescence, which is a state where cells stop dividing and can contribute to aging and disease, along with other stress-response pathways. These findings suggest that the type of dialysis a patient receives might influence their cellular health and immune function in different ways, potentially opening doors for more personalized treatment strategies in the future.
Source: link to paper